Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19237257,flow rate,It was delivered at a flow rate of 0.3 mL/min.,Determination of articaine in human plasma by liquid chromatography-mass spectrometry and its application in a preliminary pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19237257/),[ml] / [min],0.3,14611,DB00656,Trazodone
<,19237257,total run-time,"This method was fast (total run-time<3 min), accurate (bias<16%), and reproducible (intra-assay and inter-assay precision<14%) with a quantitation limit of 78.1 ng/mL.",Determination of articaine in human plasma by liquid chromatography-mass spectrometry and its application in a preliminary pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19237257/),min,3,14612,DB00656,Trazodone
,6688260,area under the plasma concentration/time curve,"The mean area under the plasma concentration/time curve was 10.07 micrograms h ml-1 and 10.44 micrograms h ml-1, for Molipaxin capsules and trazodone liquid, respectively.",A comparative bioavailability study of Molipaxin capsules and a trazodone liquid formulation in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688260/),[h·μg] / [ml],10.07,25991,DB00656,Trazodone
,6688260,area under the plasma concentration/time curve,"The mean area under the plasma concentration/time curve was 10.07 micrograms h ml-1 and 10.44 micrograms h ml-1, for Molipaxin capsules and trazodone liquid, respectively.",A comparative bioavailability study of Molipaxin capsules and a trazodone liquid formulation in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688260/),[h·μg] / [ml],10.44,25992,DB00656,Trazodone
,6688260,observed maximum plasma concentration,"There was considerable individual variation between the observed maximum plasma concentration of Molipaxin capsules and trazodone liquid but the mean values of 1.61 micrograms/ml and 1.66 micrograms/ml, respectively, were very similar.",A comparative bioavailability study of Molipaxin capsules and a trazodone liquid formulation in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688260/),[μg] / [ml],1.61,25993,DB00656,Trazodone
,6688260,observed maximum plasma concentration,"There was considerable individual variation between the observed maximum plasma concentration of Molipaxin capsules and trazodone liquid but the mean values of 1.61 micrograms/ml and 1.66 micrograms/ml, respectively, were very similar.",A comparative bioavailability study of Molipaxin capsules and a trazodone liquid formulation in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688260/),[μg] / [ml],1.66,25994,DB00656,Trazodone
,6688260,time to observed maximum plasma concentrations,"The time to observed maximum plasma concentrations varied from 15 min to 4 h, but there was no statistical difference between the two formulations.",A comparative bioavailability study of Molipaxin capsules and a trazodone liquid formulation in normal volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688260/),min,15,25995,DB00656,Trazodone
,6688260,time to observed maximum plasma concentrations,"The time to observed maximum plasma concentrations varied from 15 min to 4 h, but there was no statistical difference between the two formulations.",A comparative bioavailability study of Molipaxin capsules and a trazodone liquid formulation in normal volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688260/),h,4,25996,DB00656,Trazodone
,6688260,terminal phase half-life,The terminal phase half-life was 7.16 h for Molipaxin capsules and 6.73 h for trazodone liquid.,A comparative bioavailability study of Molipaxin capsules and a trazodone liquid formulation in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688260/),h,7.16,25997,DB00656,Trazodone
,6688260,terminal phase half-life,The terminal phase half-life was 7.16 h for Molipaxin capsules and 6.73 h for trazodone liquid.,A comparative bioavailability study of Molipaxin capsules and a trazodone liquid formulation in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688260/),h,6.73,25998,DB00656,Trazodone
,15645510,m/z,"The multiple reaction monitoring was based on the transitions m/z 624.7 --> 84.3 and 372.1 --> 176.1 for apicidin and trazodone, respectively.","Development of a liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of apicidin, a novel histone deacetylase inhibitor, in rat serum: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15645510/),,624.7,27779,DB00656,Trazodone
,15645510,m/z,"The multiple reaction monitoring was based on the transitions m/z 624.7 --> 84.3 and 372.1 --> 176.1 for apicidin and trazodone, respectively.","Development of a liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of apicidin, a novel histone deacetylase inhibitor, in rat serum: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15645510/),,84.3,27780,DB00656,Trazodone
,15645510,m/z,"The multiple reaction monitoring was based on the transitions m/z 624.7 --> 84.3 and 372.1 --> 176.1 for apicidin and trazodone, respectively.","Development of a liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of apicidin, a novel histone deacetylase inhibitor, in rat serum: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15645510/),,372.1,27781,DB00656,Trazodone
,15645510,m/z,"The multiple reaction monitoring was based on the transitions m/z 624.7 --> 84.3 and 372.1 --> 176.1 for apicidin and trazodone, respectively.","Development of a liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of apicidin, a novel histone deacetylase inhibitor, in rat serum: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15645510/),,176.1,27782,DB00656,Trazodone
,15701774,occupancy,The mACh receptor occupancy was estimated to be decreased from 0.22% to 0.020% by replacing paroxetine with fluvoxamine.,Improvement of dry mouth by replacing paroxetine with fluvoxamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15701774/),%,0.22,29064,DB00656,Trazodone
,15701774,occupancy,The mACh receptor occupancy was estimated to be decreased from 0.22% to 0.020% by replacing paroxetine with fluvoxamine.,Improvement of dry mouth by replacing paroxetine with fluvoxamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15701774/),%,0.020,29065,DB00656,Trazodone
,9832363,flow-rate,"The residue was reconstituted in 25% acetonitrile in 10 mM ammonium formate (pH 4.0), and an aliquot was injected onto a BDS Hypersil C18 column at a flow-rate of 0.3 ml/min.",Sensitive liquid chromatographic-mass spectrometric assay for the simultaneous quantitation of nefazodone and its metabolites hydroxynefazodone m-chlorophenylpiperazine and triazole-dione in human plasma using single-ion monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832363/),[ml] / [min],0.3,34253,DB00656,Trazodone
,9832363,extraction recovery,The extraction recovery of the various analytes ranged from 67.3 to 86.5%.,Sensitive liquid chromatographic-mass spectrometric assay for the simultaneous quantitation of nefazodone and its metabolites hydroxynefazodone m-chlorophenylpiperazine and triazole-dione in human plasma using single-ion monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832363/),%,67.3 to 86.5,34254,DB00656,Trazodone
,19051591,steady-state skin permeation rate,A steady-state skin permeation rate of 134.09 +/- 2.49 microg/cm2/h was achieved from the matrix patch across mouse epidermis after an initial lag time of approximately 3.5 h.,Ex vivo and in vivo evaluation of transdermal formulation of trazodone hydrochloride. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19051591/),[μg] / [cm2·h],134.09,44570,DB00656,Trazodone
,19051591,initial lag time,A steady-state skin permeation rate of 134.09 +/- 2.49 microg/cm2/h was achieved from the matrix patch across mouse epidermis after an initial lag time of approximately 3.5 h.,Ex vivo and in vivo evaluation of transdermal formulation of trazodone hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19051591/),h,3.5,44571,DB00656,Trazodone
,19051591,steady-state transdermal TZN concentration,The steady-state transdermal TZN concentration of 2.3 microg/mL was achieved in rabbit from the matrix patch after an initial lag time of approximately 2 h.,Ex vivo and in vivo evaluation of transdermal formulation of trazodone hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19051591/),[μg] / [ml],2.3,44572,DB00656,Trazodone
,19051591,initial lag time,The steady-state transdermal TZN concentration of 2.3 microg/mL was achieved in rabbit from the matrix patch after an initial lag time of approximately 2 h.,Ex vivo and in vivo evaluation of transdermal formulation of trazodone hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19051591/),h,2,44573,DB00656,Trazodone
,19051591,Cmax,The Cmax of peroral TZN solution was calculated to be 5.84 microg/mL at a Tmax of 2 h indicating its rapid absorption compared to the transdermal administration with a Tmax of 5 h.,Ex vivo and in vivo evaluation of transdermal formulation of trazodone hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19051591/),[μg] / [ml],5.84,44574,DB00656,Trazodone
,19051591,Tmax,The Cmax of peroral TZN solution was calculated to be 5.84 microg/mL at a Tmax of 2 h indicating its rapid absorption compared to the transdermal administration with a Tmax of 5 h.,Ex vivo and in vivo evaluation of transdermal formulation of trazodone hydrochloride. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19051591/),h,2,44575,DB00656,Trazodone
,19051591,Tmax,The Cmax of peroral TZN solution was calculated to be 5.84 microg/mL at a Tmax of 2 h indicating its rapid absorption compared to the transdermal administration with a Tmax of 5 h.,Ex vivo and in vivo evaluation of transdermal formulation of trazodone hydrochloride. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19051591/),h,5,44576,DB00656,Trazodone
,12723462,apparent oral clearance,"Compared to the control condition, ritonavir significantly reduced apparent oral clearance of trazodone (155 +/- 23 vs. 75 +/- 12 ml/min, p < 0.001), prolonged elimination half-life (6.7 +/- 0.7 vs. 14.9 +/- 3.9 h, p < 0.05), and increased peak plasma concentrations (842 +/- 64 vs. 1125 +/- 111 ng/ml, p < 0.05) (mean +/- SE).",Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723462/),[ml] / [min],155,44884,DB00656,Trazodone
,12723462,apparent oral clearance,"Compared to the control condition, ritonavir significantly reduced apparent oral clearance of trazodone (155 +/- 23 vs. 75 +/- 12 ml/min, p < 0.001), prolonged elimination half-life (6.7 +/- 0.7 vs. 14.9 +/- 3.9 h, p < 0.05), and increased peak plasma concentrations (842 +/- 64 vs. 1125 +/- 111 ng/ml, p < 0.05) (mean +/- SE).",Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723462/),[ml] / [min],75,44885,DB00656,Trazodone
,12723462,elimination half-life,"Compared to the control condition, ritonavir significantly reduced apparent oral clearance of trazodone (155 +/- 23 vs. 75 +/- 12 ml/min, p < 0.001), prolonged elimination half-life (6.7 +/- 0.7 vs. 14.9 +/- 3.9 h, p < 0.05), and increased peak plasma concentrations (842 +/- 64 vs. 1125 +/- 111 ng/ml, p < 0.05) (mean +/- SE).",Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723462/),h,6.7,44886,DB00656,Trazodone
,12723462,elimination half-life,"Compared to the control condition, ritonavir significantly reduced apparent oral clearance of trazodone (155 +/- 23 vs. 75 +/- 12 ml/min, p < 0.001), prolonged elimination half-life (6.7 +/- 0.7 vs. 14.9 +/- 3.9 h, p < 0.05), and increased peak plasma concentrations (842 +/- 64 vs. 1125 +/- 111 ng/ml, p < 0.05) (mean +/- SE).",Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723462/),h,14.9,44887,DB00656,Trazodone
,12723462,peak plasma concentrations,"Compared to the control condition, ritonavir significantly reduced apparent oral clearance of trazodone (155 +/- 23 vs. 75 +/- 12 ml/min, p < 0.001), prolonged elimination half-life (6.7 +/- 0.7 vs. 14.9 +/- 3.9 h, p < 0.05), and increased peak plasma concentrations (842 +/- 64 vs. 1125 +/- 111 ng/ml, p < 0.05) (mean +/- SE).",Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723462/),[ng] / [ml],842,44888,DB00656,Trazodone
,12723462,peak plasma concentrations,"Compared to the control condition, ritonavir significantly reduced apparent oral clearance of trazodone (155 +/- 23 vs. 75 +/- 12 ml/min, p < 0.001), prolonged elimination half-life (6.7 +/- 0.7 vs. 14.9 +/- 3.9 h, p < 0.05), and increased peak plasma concentrations (842 +/- 64 vs. 1125 +/- 111 ng/ml, p < 0.05) (mean +/- SE).",Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723462/),[ng] / [ml],1125,44889,DB00656,Trazodone
,29333613,maximum concentration,Trazodone was rapidly absorbed after oral administration with a maximum concentration of 2.5-4.1 μg/ml and half-life of the terminal phase of approximately 7 hr.,"Pharmacokinetics, pharmacodynamics and clinical use of trazodone and its active metabolite m-chlorophenylpiperazine in the horse. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29333613/),[μg] / [ml],2.5-4.1,52050,DB00656,Trazodone
,29333613,half-life of the terminal phase,Trazodone was rapidly absorbed after oral administration with a maximum concentration of 2.5-4.1 μg/ml and half-life of the terminal phase of approximately 7 hr.,"Pharmacokinetics, pharmacodynamics and clinical use of trazodone and its active metabolite m-chlorophenylpiperazine in the horse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29333613/),h,7,52051,DB00656,Trazodone
,1037253,half-life,"The elimination of radioactivity occurs in a biphasic manner with a half-life of 1 h for the earlier and 13 h for the second phase, no matter what application route had been chosen.",[Pharmacokinetics and metabolism of trazodone in man (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1037253/),h,1,55504,DB00656,Trazodone
,1037253,half-life,"The elimination of radioactivity occurs in a biphasic manner with a half-life of 1 h for the earlier and 13 h for the second phase, no matter what application route had been chosen.",[Pharmacokinetics and metabolism of trazodone in man (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1037253/),h,13,55505,DB00656,Trazodone
,24762492,flow rate,"Vandetanib and the internal standard (I.S.) trazodone hydrochloride were separated with gradient elution (on a C18 Atlantis column using a mobile phase of acetonitrile/0.5% triethylamine, pH 3.0, with a flow rate of 1.0 ml/min), then detected at 341 nm.",Validation of a high-performance liquid chromatographic ultraviolet detection method for the quantification of vandetanib in rat plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24762492/),[ml] / [min],1.0,57727,DB00656,Trazodone
,24762492,absolute recovery,The mean absolute recovery was 96.65%.,Validation of a high-performance liquid chromatographic ultraviolet detection method for the quantification of vandetanib in rat plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24762492/),%,96.65,57728,DB00656,Trazodone
,6487481,Cmax,"For formulation A, B and solution, the relative (trazodone/D4-trazodone) Cmax values were 0.84 +/- 0.09, 0.90 +/- 0.05 and 1.05 +/- 0.04.",Comparative bioavailability of trazodone formulations using stable isotope methodology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487481/),,0.84,74873,DB00656,Trazodone
,6487481,Cmax,"For formulation A, B and solution, the relative (trazodone/D4-trazodone) Cmax values were 0.84 +/- 0.09, 0.90 +/- 0.05 and 1.05 +/- 0.04.",Comparative bioavailability of trazodone formulations using stable isotope methodology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487481/),,0.90,74874,DB00656,Trazodone
,6487481,Cmax,"For formulation A, B and solution, the relative (trazodone/D4-trazodone) Cmax values were 0.84 +/- 0.09, 0.90 +/- 0.05 and 1.05 +/- 0.04.",Comparative bioavailability of trazodone formulations using stable isotope methodology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487481/),,1.05,74875,DB00656,Trazodone
,24168312,elimination half-life,"Following IV administration, the mean ± SD elimination half-life, apparent volume of distribution, and plasma total body clearance were 169 ± 53 minutes, 2.53 ± 0.47 L/kg, and 11.15 ± 3.56 mL/min/kg, respectively.","Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168312/),min,169,86889,DB00656,Trazodone
,24168312,apparent volume of distribution,"Following IV administration, the mean ± SD elimination half-life, apparent volume of distribution, and plasma total body clearance were 169 ± 53 minutes, 2.53 ± 0.47 L/kg, and 11.15 ± 3.56 mL/min/kg, respectively.","Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168312/),[l] / [kg],2.53,86890,DB00656,Trazodone
,24168312,plasma total body clearance,"Following IV administration, the mean ± SD elimination half-life, apparent volume of distribution, and plasma total body clearance were 169 ± 53 minutes, 2.53 ± 0.47 L/kg, and 11.15 ± 3.56 mL/min/kg, respectively.","Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168312/),[ml] / [kg·min],11.15,86891,DB00656,Trazodone
,24168312,elimination half-life,"Following oral administration, the mean ± SD elimination half-life and absolute bioavailability were 166 ± 47 minutes and 84.6 ± 13.2%, respectively.","Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168312/),min,166,86892,DB00656,Trazodone
,24168312,absolute bioavailability,"Following oral administration, the mean ± SD elimination half-life and absolute bioavailability were 166 ± 47 minutes and 84.6 ± 13.2%, respectively.","Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168312/),%,84.6,86893,DB00656,Trazodone
,24168312,Maximum plasma concentration,"Maximum plasma concentration following oral administration was 1.3 ± 0.5 μ/mL, and time to maximum plasma concentration was 445 ± 271 minutes.","Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168312/),[μ] / [ml],1.3,86894,DB00656,Trazodone
,24168312,time to maximum plasma concentration,"Maximum plasma concentration following oral administration was 1.3 ± 0.5 μ/mL, and time to maximum plasma concentration was 445 ± 271 minutes.","Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24168312/),min,445,86895,DB00656,Trazodone
,7032872,elimination half-life,Trazodone is excreted primarily as metabolites by the kidneys and possesses a biphasic elimination half-life of 4.4 hours for the first 10 hours and 7.5 hours for the next 24 hours.,"Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7032872/),h,4.4,93210,DB00656,Trazodone
,7032872,elimination half-life,Trazodone is excreted primarily as metabolites by the kidneys and possesses a biphasic elimination half-life of 4.4 hours for the first 10 hours and 7.5 hours for the next 24 hours.,"Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7032872/),h,7.5,93211,DB00656,Trazodone
,30605036,terminal half-life,Mean ± SD terminal half-life of trazodone was 5.65 ± 1.75 hours.,Determination of the pharmacokinetics of a single oral dose of trazodone and its effect on the activity level of domestic pigeons (Columba livia). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30605036/),h,5.65,126580,DB00656,Trazodone
,24291719,flow rate,"The HPLC separation was performed on a CAPCELL PAK SCX column (250mm×4.6mm, 5.0μm, Shiseido, Japan) with a mobile phase of acetonitrile/80mmol/L ammonium phosphate (pH adjusted to 6.0) (60:40, v/v) at a flow rate of 1.2mL/min.",Quantitative analysis of trazodone in human plasma by using HPLC-fluorescence detector coupled with strong cation exchange chromatographic column: application to a pharmacokinetic study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24291719/),[ml] / [min],1.2,136669,DB00656,Trazodone
,24291719,extraction recovery,The extraction recovery was 72.6-88.3% and the method was over the concentration range of 5.0-2486ng/mL with a lower limit of quantitation (LLOQ) of 5.0ng/mL using 300μL of plasma.,Quantitative analysis of trazodone in human plasma by using HPLC-fluorescence detector coupled with strong cation exchange chromatographic column: application to a pharmacokinetic study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24291719/),%,72.6-88.3,136670,DB00656,Trazodone
,16506266,ssow rate,"Separation was carried out on a BDS Hypersil C(18) analytical column (2 x 50 mm, 3 microm) and an effective chromatographic separation of muraglitazar (3.31 min) and trazadone (2.27 min) was achieved at a ssow rate of 0.3 mL/min.",Liquid chromatography/mass spectrometry for the quantitation of muraglitazar in monkey plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506266/),[ml] / [min],0.3,137856,DB00656,Trazodone
,16506266,extraction recoveries,"The average extraction recoveries of muraglitazar and IS were 83.3 and 91.9%, respectively.",Liquid chromatography/mass spectrometry for the quantitation of muraglitazar in monkey plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506266/),%,83.3,137857,DB00656,Trazodone
,16506266,extraction recoveries,"The average extraction recoveries of muraglitazar and IS were 83.3 and 91.9%, respectively.",Liquid chromatography/mass spectrometry for the quantitation of muraglitazar in monkey plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16506266/),%,91.9,137858,DB00656,Trazodone
,17386756,gamma(2),"Under the optimized conditions, a linear response for trazodone over the range of 20-2000 ng mL(-1) was achieved with a gamma(2) value of 0.9996.",The investigation of electrospun polymer nanofibers as a solid-phase extraction sorbent for the determination of trazodone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17386756/),,0.9996,142766,DB00656,Trazodone
,17386756,extraction recoveries,The extraction recoveries of 58.3-75.2% and the relative recoveries of 94.6-105.5% were obtained.,The investigation of electrospun polymer nanofibers as a solid-phase extraction sorbent for the determination of trazodone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17386756/),%,58.3-75.2,142767,DB00656,Trazodone
,17386756,relative recoveries,The extraction recoveries of 58.3-75.2% and the relative recoveries of 94.6-105.5% were obtained.,The investigation of electrospun polymer nanofibers as a solid-phase extraction sorbent for the determination of trazodone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17386756/),%,94.6-105.5,142768,DB00656,Trazodone
,17386756,limit of detection (LOD),The limit of detection (LOD) was determined to be 8 ng mL(-1).,The investigation of electrospun polymer nanofibers as a solid-phase extraction sorbent for the determination of trazodone in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17386756/),[ng] / [ml],8,142769,DB00656,Trazodone
,3608351,volume of distribution (Varea),"Among men, trazodone volume of distribution (Varea) was increased in elderly vs. young subjects (1.15 vs. 0.89 L/kg; P less than 0.05), and clearance decreased (1.65 vs. 2.31 ml/min/kg; P less than 0.05), thereby increasing elimination half-life (t1/2) in elderly men (8.2 vs. 4.7 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[l] / [kg],1.15,157633,DB00656,Trazodone
,3608351,volume of distribution (Varea),"Among men, trazodone volume of distribution (Varea) was increased in elderly vs. young subjects (1.15 vs. 0.89 L/kg; P less than 0.05), and clearance decreased (1.65 vs. 2.31 ml/min/kg; P less than 0.05), thereby increasing elimination half-life (t1/2) in elderly men (8.2 vs. 4.7 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[l] / [kg],0.89,157634,DB00656,Trazodone
,3608351,clearance,"Among men, trazodone volume of distribution (Varea) was increased in elderly vs. young subjects (1.15 vs. 0.89 L/kg; P less than 0.05), and clearance decreased (1.65 vs. 2.31 ml/min/kg; P less than 0.05), thereby increasing elimination half-life (t1/2) in elderly men (8.2 vs. 4.7 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[ml] / [kg·min],1.65,157635,DB00656,Trazodone
,3608351,clearance,"Among men, trazodone volume of distribution (Varea) was increased in elderly vs. young subjects (1.15 vs. 0.89 L/kg; P less than 0.05), and clearance decreased (1.65 vs. 2.31 ml/min/kg; P less than 0.05), thereby increasing elimination half-life (t1/2) in elderly men (8.2 vs. 4.7 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[ml] / [kg·min],2.31,157636,DB00656,Trazodone
,3608351,elimination half-life (t1/2),"Among men, trazodone volume of distribution (Varea) was increased in elderly vs. young subjects (1.15 vs. 0.89 L/kg; P less than 0.05), and clearance decreased (1.65 vs. 2.31 ml/min/kg; P less than 0.05), thereby increasing elimination half-life (t1/2) in elderly men (8.2 vs. 4.7 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),h,8.2,157637,DB00656,Trazodone
,3608351,elimination half-life (t1/2),"Among men, trazodone volume of distribution (Varea) was increased in elderly vs. young subjects (1.15 vs. 0.89 L/kg; P less than 0.05), and clearance decreased (1.65 vs. 2.31 ml/min/kg; P less than 0.05), thereby increasing elimination half-life (t1/2) in elderly men (8.2 vs. 4.7 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),h,4.7,157638,DB00656,Trazodone
,3608351,Varea,"Varea in women was also increased in the elderly (1.5 vs. 1.27 L/kg; P less than 0.02), causing increased t1/2 (7.6 vs. 5.9 hours; P less than 0.05), but clearance was unrelated to age.","Trazodone kinetics: effect of age, gender, and obesity. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[l] / [kg],1.5,157639,DB00656,Trazodone
,3608351,Varea,"Varea in women was also increased in the elderly (1.5 vs. 1.27 L/kg; P less than 0.02), causing increased t1/2 (7.6 vs. 5.9 hours; P less than 0.05), but clearance was unrelated to age.","Trazodone kinetics: effect of age, gender, and obesity. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[l] / [kg],1.27,157640,DB00656,Trazodone
,3608351,t1/2,"Varea in women was also increased in the elderly (1.5 vs. 1.27 L/kg; P less than 0.02), causing increased t1/2 (7.6 vs. 5.9 hours; P less than 0.05), but clearance was unrelated to age.","Trazodone kinetics: effect of age, gender, and obesity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),h,7.6,157641,DB00656,Trazodone
,3608351,t1/2,"Varea in women was also increased in the elderly (1.5 vs. 1.27 L/kg; P less than 0.02), causing increased t1/2 (7.6 vs. 5.9 hours; P less than 0.05), but clearance was unrelated to age.","Trazodone kinetics: effect of age, gender, and obesity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),h,5.9,157642,DB00656,Trazodone
,3608351,Absolute bioavailability,Absolute bioavailability of oral trazodone averaged 70% to 90% and was unrelated to age or sex.,"Trazodone kinetics: effect of age, gender, and obesity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),%,70,157643,DB00656,Trazodone
,3608351,Absolute bioavailability,Absolute bioavailability of oral trazodone averaged 70% to 90% and was unrelated to age or sex.,"Trazodone kinetics: effect of age, gender, and obesity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),%,90,157644,DB00656,Trazodone
,3608351,Varea,"In 23 obese subjects (mean weight 112 kg) vs. 23 matched control subjects of normal weight (mean 65 kg), Varea was greatly increased (162 vs. 67 L; 1.43 vs. 1.04 L/kg; P less than 0.001) and was highly correlated with body weight (r = 0.91).","Trazodone kinetics: effect of age, gender, and obesity. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),l,162,157645,DB00656,Trazodone
,3608351,Varea,"In 23 obese subjects (mean weight 112 kg) vs. 23 matched control subjects of normal weight (mean 65 kg), Varea was greatly increased (162 vs. 67 L; 1.43 vs. 1.04 L/kg; P less than 0.001) and was highly correlated with body weight (r = 0.91).","Trazodone kinetics: effect of age, gender, and obesity. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),l,67,157646,DB00656,Trazodone
,3608351,Varea,"In 23 obese subjects (mean weight 112 kg) vs. 23 matched control subjects of normal weight (mean 65 kg), Varea was greatly increased (162 vs. 67 L; 1.43 vs. 1.04 L/kg; P less than 0.001) and was highly correlated with body weight (r = 0.91).","Trazodone kinetics: effect of age, gender, and obesity. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[l] / [kg],1.43,157647,DB00656,Trazodone
,3608351,Varea,"In 23 obese subjects (mean weight 112 kg) vs. 23 matched control subjects of normal weight (mean 65 kg), Varea was greatly increased (162 vs. 67 L; 1.43 vs. 1.04 L/kg; P less than 0.001) and was highly correlated with body weight (r = 0.91).","Trazodone kinetics: effect of age, gender, and obesity. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[l] / [kg],1.04,157648,DB00656,Trazodone
,3608351,Clearance,"Clearance was unchanged between groups (146 vs. 136 ml/min), but the increased Varea caused prolonged t1/2 in obese subjects (13.3 vs. 5.9 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[ml] / [min],146,157649,DB00656,Trazodone
,3608351,Clearance,"Clearance was unchanged between groups (146 vs. 136 ml/min), but the increased Varea caused prolonged t1/2 in obese subjects (13.3 vs. 5.9 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),[ml] / [min],136,157650,DB00656,Trazodone
,3608351,t1/2,"Clearance was unchanged between groups (146 vs. 136 ml/min), but the increased Varea caused prolonged t1/2 in obese subjects (13.3 vs. 5.9 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),h,13.3,157651,DB00656,Trazodone
,3608351,t1/2,"Clearance was unchanged between groups (146 vs. 136 ml/min), but the increased Varea caused prolonged t1/2 in obese subjects (13.3 vs. 5.9 hours; P less than 0.001).","Trazodone kinetics: effect of age, gender, and obesity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608351/),h,5.9,157652,DB00656,Trazodone
,2211561,half-life,The 3- to 9-hour half-life of trazodone and its pharmacokinetics favors a dose weighted at bedtime.,Trazodone dosing regimen: experience with single daily administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211561/),h,3- to 9-,169340,DB00656,Trazodone
,33112166,maximum plasma trazodone concentration,"Median (interquartile [25th to 75th percentile] range [IQR]) maximum plasma trazodone concentration and volume of distribution and clearance corrected for bioavailability were 1.00 μg/mL (0.66 to 1.40 μg/mL), 10.3 L/kg (7.37 to 14.4 L/kg), and 639 mL/kg/h (594 to 719 mL/kg/h), respectively.",Pharmacokinetics and efficacy of trazodone following rectal administration of a single dose to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33112166/),[μg] / [ml],1.00,171411,DB00656,Trazodone
,33112166,volume of distribution,"Median (interquartile [25th to 75th percentile] range [IQR]) maximum plasma trazodone concentration and volume of distribution and clearance corrected for bioavailability were 1.00 μg/mL (0.66 to 1.40 μg/mL), 10.3 L/kg (7.37 to 14.4 L/kg), and 639 mL/kg/h (594 to 719 mL/kg/h), respectively.",Pharmacokinetics and efficacy of trazodone following rectal administration of a single dose to healthy dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33112166/),[l] / [kg],10.3,171412,DB00656,Trazodone
,33112166,clearance corrected for bioavailability,"Median (interquartile [25th to 75th percentile] range [IQR]) maximum plasma trazodone concentration and volume of distribution and clearance corrected for bioavailability were 1.00 μg/mL (0.66 to 1.40 μg/mL), 10.3 L/kg (7.37 to 14.4 L/kg), and 639 mL/kg/h (594 to 719 mL/kg/h), respectively.",Pharmacokinetics and efficacy of trazodone following rectal administration of a single dose to healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33112166/),[ml] / [h·kg],639,171413,DB00656,Trazodone
,33112166,time to maximum plasma trazodone concentration,"Median time to maximum plasma trazodone concentration and elimination half-life were 15 minutes (range, 15 to 30 minutes) and 12 hours (IQR, 7.99 to 12.7 hours), respectively.",Pharmacokinetics and efficacy of trazodone following rectal administration of a single dose to healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33112166/),min,15,171414,DB00656,Trazodone
,33112166,elimination half-life,"Median time to maximum plasma trazodone concentration and elimination half-life were 15 minutes (range, 15 to 30 minutes) and 12 hours (IQR, 7.99 to 12.7 hours), respectively.",Pharmacokinetics and efficacy of trazodone following rectal administration of a single dose to healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33112166/),h,12,171415,DB00656,Trazodone
,10745059,K(m),Formation of mCPP from trazodone in liver microsomes had a mean (+/- SE) K(m) value of 163 (+/- 21) micromol/L.,In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10745059/),[μM] / [l],163,176334,DB00656,Trazodone
,10745059,inhibition constant (K(i)),"Ketoconazole, a relatively specific CYP3A inhibitor, impaired mCPP formation consistent with a competitive mechanism, having an inhibition constant (K(i)) of 0.12 (+/- 0.01) micromol/L.",In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10745059/),[μM] / [l],0.12,176335,DB00656,Trazodone
,10745059,K(m),"Among heterologously expressed human cytochromes, only CYP3A4 mediated formation of mCPP from trazodone; the K(m) was 180 micromol/L, consistent with the value in microsomes.",In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10745059/),[μM] / [l],180,176336,DB00656,Trazodone
,10745059,K(i),The HIVPI ritonavir was a potent inhibitor of mCPP formation in liver microsomes (K(i) = 0.14 +/- 0.04 micromol/L).,In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10745059/),[μM] / [l],0.14,176337,DB00656,Trazodone
over,33480570,plasma concentrations,"All animals achieved plasma concentrations over 130 ng/ml, a level considered therapeutic in humans and dogs, for a mean of 6.4 ± 5.0 hr.",PHARMACOKINETICS AND CLINICAL EFFECTS OF A SINGLE ORAL DOSE OF TRAZODONE IN THE DOMESTIC GOAT (CAPRA HIRCUS) AS A MODEL FOR WILD RUMINANTS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33480570/),[ng] / [ml],130,182014,DB00656,Trazodone
,33480570,terminal half-life,Mean terminal half-life was 10.55 ± 6.80 hr.,PHARMACOKINETICS AND CLINICAL EFFECTS OF A SINGLE ORAL DOSE OF TRAZODONE IN THE DOMESTIC GOAT (CAPRA HIRCUS) AS A MODEL FOR WILD RUMINANTS. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33480570/),h,10.55,182015,DB00656,Trazodone
,28945130,total clearance,"RESULTS After IV administration, total clearance of trazodone was 6.85 ± 2.80 mL/min/kg, volume of distribution at steady state was 1.06 ± 0.07 L/kg, and elimination half-life was 8.58 ± 1.88 hours.",Pharmacokinetics and selected pharmacodynamics of trazodone following intravenous and oral administration to horses undergoing fitness training. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28945130/),[ml] / [kg·min],6.85,191737,DB00656,Trazodone
,28945130,volume of distribution at steady state,"RESULTS After IV administration, total clearance of trazodone was 6.85 ± 2.80 mL/min/kg, volume of distribution at steady state was 1.06 ± 0.07 L/kg, and elimination half-life was 8.58 ± 1.88 hours.",Pharmacokinetics and selected pharmacodynamics of trazodone following intravenous and oral administration to horses undergoing fitness training. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28945130/),[l] / [kg],1.06,191738,DB00656,Trazodone
,28945130,elimination half-life,"RESULTS After IV administration, total clearance of trazodone was 6.85 ± 2.80 mL/min/kg, volume of distribution at steady state was 1.06 ± 0.07 L/kg, and elimination half-life was 8.58 ± 1.88 hours.",Pharmacokinetics and selected pharmacodynamics of trazodone following intravenous and oral administration to horses undergoing fitness training. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28945130/),h,8.58,191739,DB00656,Trazodone
,28945130,Terminal phase half-life,Terminal phase half-life was 7.11 ± 1.70 hours after oral administration.,Pharmacokinetics and selected pharmacodynamics of trazodone following intravenous and oral administration to horses undergoing fitness training. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28945130/),h,7.11,191740,DB00656,Trazodone
,8372048,t 1/2,"The following main parameters were calculated at steady state for psychiatric patients (mean +/- S.D.): t 1/2 = 7.0 +/- 1.2, V beta/F = 0.50 +/- 0.13 l/kg and Clt/F = 3.2 +/- 0.5 l/hr.",Pharmacokinetics of trazodone during multiple dosing to psychiatric patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8372048/),,7.0,197318,DB00656,Trazodone
,8372048,V beta/F,"The following main parameters were calculated at steady state for psychiatric patients (mean +/- S.D.): t 1/2 = 7.0 +/- 1.2, V beta/F = 0.50 +/- 0.13 l/kg and Clt/F = 3.2 +/- 0.5 l/hr.",Pharmacokinetics of trazodone during multiple dosing to psychiatric patients. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8372048/),[l] / [kg],0.50,197319,DB00656,Trazodone
,8372048,Clt/F,"The following main parameters were calculated at steady state for psychiatric patients (mean +/- S.D.): t 1/2 = 7.0 +/- 1.2, V beta/F = 0.50 +/- 0.13 l/kg and Clt/F = 3.2 +/- 0.5 l/hr.",Pharmacokinetics of trazodone during multiple dosing to psychiatric patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8372048/),[l] / [h],3.2,197320,DB00656,Trazodone
,8372048,oral availability,These pharmacokinetic parameters did not differ significantly from those earlier reported in healthy subjects after a single dose administration of 100 mg when based on an oral availability of trazodone of 65%.,Pharmacokinetics of trazodone during multiple dosing to psychiatric patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8372048/),%,65,197321,DB00656,Trazodone
,11765144,terminal half-life,The terminal half-life of the total radioactivity from plasma was 21.7 +/- 2.8h with an apparent clearance of 1.01 +/- 0.08 ml min(-1).,"Evaluation of the absorption, excretion and metabolism of [14C] etoperidone in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765144/),h,21.7,212856,DB00656,Trazodone
,11765144,apparent clearance,The terminal half-life of the total radioactivity from plasma was 21.7 +/- 2.8h with an apparent clearance of 1.01 +/- 0.08 ml min(-1).,"Evaluation of the absorption, excretion and metabolism of [14C] etoperidone in man. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765144/),[ml] / [min],1.01,212857,DB00656,Trazodone
,11765144,Recoveries,"Recoveries of total radioactivity in urine and faeces were 78.8 +/- 3.6% and 9.6 +/- 4.1% of the dose, respectively.","Evaluation of the absorption, excretion and metabolism of [14C] etoperidone in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765144/),%,78.8,212858,DB00656,Trazodone
,11765144,Recoveries,"Recoveries of total radioactivity in urine and faeces were 78.8 +/- 3.6% and 9.6 +/- 4.1% of the dose, respectively.","Evaluation of the absorption, excretion and metabolism of [14C] etoperidone in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765144/),%,9.6,212859,DB00656,Trazodone
,26483693,Cmax,"For the test formulation, the trazodone gMean Cmax was 1480.9 ng/mL (vs. 1520.2 ng/mL for reference), AUC0-t was 18193.0 ng·h/mL (vs. 18209.8 ng·h/mL) and AUC0-∞ was 19346.3 ng·h/mL (vs. 19393.4 ng·h/mL).","Pharmacokinetics of single oral dose trazodone: a randomized, two-period, cross-over trial in healthy, adult, human volunteers under fed condition. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26483693/),[ng] / [ml],1480.9,241077,DB00656,Trazodone
,26483693,Cmax,"For the test formulation, the trazodone gMean Cmax was 1480.9 ng/mL (vs. 1520.2 ng/mL for reference), AUC0-t was 18193.0 ng·h/mL (vs. 18209.8 ng·h/mL) and AUC0-∞ was 19346.3 ng·h/mL (vs. 19393.4 ng·h/mL).","Pharmacokinetics of single oral dose trazodone: a randomized, two-period, cross-over trial in healthy, adult, human volunteers under fed condition. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26483693/),[ng] / [ml],1520.2,241078,DB00656,Trazodone
,26483693,AUC0-t,"For the test formulation, the trazodone gMean Cmax was 1480.9 ng/mL (vs. 1520.2 ng/mL for reference), AUC0-t was 18193.0 ng·h/mL (vs. 18209.8 ng·h/mL) and AUC0-∞ was 19346.3 ng·h/mL (vs. 19393.4 ng·h/mL).","Pharmacokinetics of single oral dose trazodone: a randomized, two-period, cross-over trial in healthy, adult, human volunteers under fed condition. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26483693/),[h·ng] / [ml],18193.0,241079,DB00656,Trazodone
,26483693,AUC0-t,"For the test formulation, the trazodone gMean Cmax was 1480.9 ng/mL (vs. 1520.2 ng/mL for reference), AUC0-t was 18193.0 ng·h/mL (vs. 18209.8 ng·h/mL) and AUC0-∞ was 19346.3 ng·h/mL (vs. 19393.4 ng·h/mL).","Pharmacokinetics of single oral dose trazodone: a randomized, two-period, cross-over trial in healthy, adult, human volunteers under fed condition. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26483693/),[h·ng] / [ml],18209.8,241080,DB00656,Trazodone
,26483693,AUC0-∞,"For the test formulation, the trazodone gMean Cmax was 1480.9 ng/mL (vs. 1520.2 ng/mL for reference), AUC0-t was 18193.0 ng·h/mL (vs. 18209.8 ng·h/mL) and AUC0-∞ was 19346.3 ng·h/mL (vs. 19393.4 ng·h/mL).","Pharmacokinetics of single oral dose trazodone: a randomized, two-period, cross-over trial in healthy, adult, human volunteers under fed condition. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26483693/),[h·ng] / [ml],19346.3,241081,DB00656,Trazodone
,26483693,AUC0-∞,"For the test formulation, the trazodone gMean Cmax was 1480.9 ng/mL (vs. 1520.2 ng/mL for reference), AUC0-t was 18193.0 ng·h/mL (vs. 18209.8 ng·h/mL) and AUC0-∞ was 19346.3 ng·h/mL (vs. 19393.4 ng·h/mL).","Pharmacokinetics of single oral dose trazodone: a randomized, two-period, cross-over trial in healthy, adult, human volunteers under fed condition. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26483693/),[h·ng] / [ml],19393.4,241082,DB00656,Trazodone
,1438031,maximum serum concentrations,"Food intake significantly decreased the maximum serum concentrations of trazodone from 1.88 +/- 0.42 to 1.47 +/- 0.16 micrograms/ml, and increased the time for reaching maximum concentration from 1.3 +/- 0.8 hr to 2.0 +/- 1.5 hr.",Single dose pharmacokinetics of trazodone in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),[μg] / [ml],1.88,244681,DB00656,Trazodone
,1438031,maximum serum concentrations,"Food intake significantly decreased the maximum serum concentrations of trazodone from 1.88 +/- 0.42 to 1.47 +/- 0.16 micrograms/ml, and increased the time for reaching maximum concentration from 1.3 +/- 0.8 hr to 2.0 +/- 1.5 hr.",Single dose pharmacokinetics of trazodone in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),[μg] / [ml],1.47,244682,DB00656,Trazodone
,1438031,time for reaching maximum concentration,"Food intake significantly decreased the maximum serum concentrations of trazodone from 1.88 +/- 0.42 to 1.47 +/- 0.16 micrograms/ml, and increased the time for reaching maximum concentration from 1.3 +/- 0.8 hr to 2.0 +/- 1.5 hr.",Single dose pharmacokinetics of trazodone in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),h,1.3,244683,DB00656,Trazodone
,1438031,time for reaching maximum concentration,"Food intake significantly decreased the maximum serum concentrations of trazodone from 1.88 +/- 0.42 to 1.47 +/- 0.16 micrograms/ml, and increased the time for reaching maximum concentration from 1.3 +/- 0.8 hr to 2.0 +/- 1.5 hr.",Single dose pharmacokinetics of trazodone in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),h,2.0,244684,DB00656,Trazodone
,1438031,bioavailability,"No differences were observed in the total amount of trazodone absorbed with or without food with bioavailability values of 65 +/- 6 and 63 +/- 4 per cent, respectively.",Single dose pharmacokinetics of trazodone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),%,65,244685,DB00656,Trazodone
,1438031,bioavailability,"No differences were observed in the total amount of trazodone absorbed with or without food with bioavailability values of 65 +/- 6 and 63 +/- 4 per cent, respectively.",Single dose pharmacokinetics of trazodone in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),%,63,244686,DB00656,Trazodone
,1438031,apparent volume of distribution,"The apparent volume of distribution and total body clearance for trazodone were estimated to 0.84 +/- 0.16 l/kg and 5.3 +/- 0.9 l/hr, respectively.",Single dose pharmacokinetics of trazodone in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),[l] / [kg],0.84,244687,DB00656,Trazodone
,1438031,total body clearance,"The apparent volume of distribution and total body clearance for trazodone were estimated to 0.84 +/- 0.16 l/kg and 5.3 +/- 0.9 l/hr, respectively.",Single dose pharmacokinetics of trazodone in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),[l] / [h],5.3,244688,DB00656,Trazodone
,1438031,terminal elimination half-life,The terminal elimination half-life of 7.3 +/- 0.8 hr showed no significant differences between the different ways of administration.,Single dose pharmacokinetics of trazodone in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),h,7.3,244689,DB00656,Trazodone
less,1438031,Urinary excretion,"Urinary excretion of unchanged trazodone during 26 hr was less than 0.13 per cent of the administered dose, suggesting a high degree of trazodone metabolism.",Single dose pharmacokinetics of trazodone in healthy subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1438031/),%,0.13,244690,DB00656,Trazodone
,32488885,ΔΔQTcF,"ΔΔQTcF values of 4.5, 12.3, and 19.8 ms for the 20-, 60-, and 140-mg doses were observed at the corresponding trazodone peak plasma concentrations.",Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32488885/),ms,4.5,264164,DB00656,Trazodone
,32488885,ΔΔQTcF,"ΔΔQTcF values of 4.5, 12.3, and 19.8 ms for the 20-, 60-, and 140-mg doses were observed at the corresponding trazodone peak plasma concentrations.",Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32488885/),ms,12.3,264165,DB00656,Trazodone
,32488885,ΔΔQTcF,"ΔΔQTcF values of 4.5, 12.3, and 19.8 ms for the 20-, 60-, and 140-mg doses were observed at the corresponding trazodone peak plasma concentrations.",Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32488885/),ms,19.8,264166,DB00656,Trazodone
,15935603,recoveries,"Mean recoveries from plasma and tissue homogenates were 88 and 90%, respectively.",Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15935603/),%,88,273643,DB00656,Trazodone
,15935603,recoveries,"Mean recoveries from plasma and tissue homogenates were 88 and 90%, respectively.",Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15935603/),%,90,273644,DB00656,Trazodone
